These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 19368504)

  • 1. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
    Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
    Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
    Spradling P; Drociuk D; McLaughlin S; Lee LM; Peloquin CA; Gallicano K; Pozsik C; Onorato I; Castro KG; Ridzon R
    Clin Infect Dis; 2002 Nov; 35(9):1106-12. PubMed ID: 12384845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis.
    Narita M; Stambaugh JJ; Hollender ES; Jones D; Pitchenik AE; Ashkin D
    Clin Infect Dis; 2000 May; 30(5):779-83. PubMed ID: 10816148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
    Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
    Khachi H; O'Connell R; Ladenheim D; Orkin C
    J Antimicrob Chemother; 2009 Oct; 64(4):871-3. PubMed ID: 19628472
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1996 Oct; 45(42):921-5. PubMed ID: 8927017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
    Schluger NW
    Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
    Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
    Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.
    Singh R; Marshall N; Smith CJ; Reynolds CJ; Breen RA; Bhagani S; Cropley I; Hopkins S; Swaden L; Johnson MA; Lipman MC
    AIDS; 2013 Jan; 27(3):481-4. PubMed ID: 23014518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.